The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of addition of docetaxel (D) to hormonal therapy (HT) versus HT alone on quality of life: Results from a phase III study in non-metastatic high-risk prostate cancer (PC) patients (pts) with a rising PSA status.
Stephane Oudard
Consultant or Advisory Role - Novartis; Roche
Honoraria - Bristol-Myers Squibb; Keocyt; Pfizer; Sanofi
Florence Gillaizeau
No relevant relationships to disclose
Severine Peyrard
No relevant relationships to disclose
Igor Latorzeff
Consultant or Advisory Role - AstraZeneca; Ferring; Ipsen; Sanofi ; Takeda
Honoraria - AstraZeneca; Ferring; Ipsen; Sanofi ; Takeda
Philippe Beuzeboc
Honoraria - Sanofi
Emmanuel Sevin
No relevant relationships to disclose
Frederic Rolland
No relevant relationships to disclose
Loic Mourey
No relevant relationships to disclose
Franck Priou
No relevant relationships to disclose
Stephane Culine
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi